-transparent.png){kind=logo}
Fifty-four patients with metastatic non-oat-cell bronchogenic carcinoma were treated with cyclophosphamide, doxorubicin hydrochloride (Adriamycin), methotrexate, and procarbazine hydrochloride (CAMP). Eighteen of 51 of these patients with measurable disease showed an objective response to CAMP chemotherapy, with a median survival of 12.6 months. Eight of the 18 patients are still alive, and two have been in continuous remission for 20 and 26 months. Survival for patients with stable disease was 12 months, similar to that for patients demonstrating objective regression in response to CAMP treatment. Weight loss, performance status, and dominant site of metastases proved to be important prognostic factors. The CAMP regimen was well tolerated; there were only two drug-related deaths, both secondary to infectious complications.
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
October 1978,
Cancer treatment reports,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
January 1981,
Cancer treatment reports,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
January 1982,
Cancer chemotherapy and pharmacology,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
May 1977,
JAMA,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
January 1979,
Cancer clinical trials,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
October 1982,
Cancer treatment reports,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
November 1985,
Cancer,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
January 1981,
Cancer treatment reports,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
December 1976,
Cancer,
J D Bitran, and
R K Desser, and
T DeMeester, and
H M Golomb
January 1977,
Clinical bulletin,
